Antibodies - Strategic Insights Report (Page 3)

Antibodies

Breakthrough in COVID-19 Vaccine Development: University of Science and Technology of China Research

Research from the University of Science and Technology of China has led to the development of self-adjuvant-effect biomimetic nanovaccines capable of counteracting current and prospective viral variants of SARS-CoV-2. This innovative approach utilizes synthetic biology technology to create nanoparticles that significantly promote the recruitment of dendritic cells to secondary lymphoid

Diseases

Resources for Amyloid-Antibody Therapies in Early Alzheimer's Disease Lacking

Austria's Alzheimer Society conducted a survey of hospital-based departments of neurology and psychiatry to assess their readiness for disease-modifying therapies with amyloid-antibodies for patients with early Alzheimer's disease. The research, led by Gerhard Ransmayr, Medical Faculty, Johannes-Kepler-University, found that many centers lack the necessary resources, including

Diseases

Neuropathic Pain in CASPR2 Antibody Disease Spectrum: A Systematic Review

Researchers at the University of Florence have conducted a systematic review to better understand neuropathic pain associated with Contactin-associated protein-like 2 (CASPR2) antibodies. The study found that 7.4% of patients with CASPR2 antibody disease spectrum presented with isolated neuropathic pain, which was typically severe and presented as distal burning

Diseases

Patent Application for HCMV Gp34- and Gp68-Specific Antibodies Reveals Novel Therapeutic and Diagnostic Approaches

A patent application filed by a team of researchers from the Albert-Ludwigs-Universitaet Freiburg in Germany, led by Harmut Hengel, has disclosed novel antibodies and antigen binding fragments targeting the extracellular domains of human cytomegalovirus (HCMV) glycoproteins gp34 and gp68. The application, filed on June 10, 2022, and made available online

Diseases

Dualitas Therapeutics Launches with $65 Million Series A Financing

Dualitas Therapeutics, a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies, has launched from stealth mode with a $65 million Series A financing. The funding was co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund,

Antibodies

New Insights into Monkeypox Virus Antibody Levels and Vaccine Efficacy

Research published by the Shenzhen Center for Disease Control and Prevention has shed light on the antibody levels of the monkeypox virus (MPXV) in the population and the protective efficacy of smallpox vaccination. The study, published in Virology Journal, reviewed existing literature from 1958 to 2025 and found a significant

Antibodies

The Flu Shot Conundrum: Timing and Effectiveness Matter

As the annual flu season approaches, the debate on when to receive the flu shot has sparked a discussion on the effectiveness of the vaccine and the timing of vaccinations. Research suggests that flu shot effectiveness wanes significantly over time, just like Covid-19 shots, particularly in high-risk individuals. This has

Antibodies

The Timing of Flu Shots: A Critical Review

As flu season approaches, many healthcare workers face a dilemma: receive the annual flu shot by the end of October or get vaccinated early, despite the evidence suggesting that effectiveness over time decreases in high-risk individuals. A substantial body of research indicates that antibodies produced in response to flu vaccinations

See all